Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2015-12-23 Board/Management Inform…
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K 12.23.15
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the resignation of a director and chairman, the appointment of an interim chairman, and the election of a new board member along with their employment agreements. These are changes in the company's board of directors and senior management. There is no financial data or earnings information, nor is it a full annual or quarterly report. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board and principal officers.
2015-12-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and references a press release about the company's third quarter results. The document states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The length of the document is 3132 characters, which is relatively short and mostly contains the filing cover page and references to the press release. There are no actual financial statements or detailed financial data within this document itself, only a reference to a press release. According to the rules, if a document is short and only announces or references a report or press release, it should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER). The document is not the earnings release itself but a filing announcing it. Therefore, the correct classification is Regulatory Filings (RNS).
2015-11-09 English
10-Q
Interim / Quarterly Report Q3 2015
2015-11-05 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by Caladrius Biosciences, Inc. It details the terms of a $30 million offering plus commitment shares to Aspire Capital Fund, LLC. The document includes information about the offering, risk factors, use of proceeds, and company background. It is a detailed disclosure document related to capital raising and financing activities, not a financial report, earnings release, or management discussion. The presence of terms like 'prospectus supplement', 'offering', 'common stock purchase agreement', and the description of the offering and use of proceeds clearly indicate this is a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-11-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details changes in senior management positions, including promotions and resignations of key officers, along with related compensation and severance agreements. There is no financial data or earnings information, nor is it an announcement of a report publication. The primary focus is on management changes, which aligns with the Board/Management Information category (MANG). The document length is sufficient and contains detailed information about management changes, confirming it is not a brief announcement or certification. Therefore, the correct classification is MANG with high confidence.
2015-10-08 English
Regulatory Filings 2015
Regulatory Filings
2015-08-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.